Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis

Nicola Aceto,1,2 Aditya Bardia,1,2 David T. Miyamoto,1,5 Maria C. Donaldson,1,2 Ben S. Wittner,1,2 Joel A. Spencer,3,4 Min Yu,1,2 Adam Pely,3,4 Amanda Engstrom,1,2 Huili Zhu,1,2 Brian W. Brannigan,1,2 Ravi Kapur,6 Shannon L. Stott,1,2,6 Toshi Shioda,1,2 Sridhar Ramaswamy,1,2 David T. Ting,1,2 Charles P. Lin,3,4 Mehmet Toner,6,7 Daniel A. Haber,1,2,8,* and Shyamala Maheswaran1,7,*

1Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02129, USA
2Department of Medicine, Harvard Medical School, Boston, MA 02129, USA
3Advanced Microscopy Program, Wellman Center for Photomedicine and Center for Systems Biology, Massachusetts General Hospital, Boston, MA 02114, USA
4Harvard Stem Cell Institute, 1350 Massachusetts Avenue, Cambridge, MA 02138, USA
5Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA
6Center for Bioengineering in Medicine, Harvard Medical School, Boston, MA 02129, USA
7Department of Surgery, Harvard Medical School, Boston, MA 02129, USA
8Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA

*Correspondence: dhaber@mgh.harvard.edu (D.A.H.), maheswaran@helix.mgh.harvard.edu (S.M.)
http://dx.doi.org/10.1016/j.cell.2014.07.013

SUMMARY

Circulating tumor cell clusters (CTC clusters) are present in the blood of patients with cancer but their contribution to metastasis is not well defined. Using mouse models with tagged mammary tumors, we demonstrate that CTC clusters arise from oligoclonal tumor cell groupings and not from intravascular aggregation events. Although rare in the circulation compared with single CTCs, CTC clusters have 23- to 50-fold increased metastatic potential. In patients with breast cancer, single-cell resolution RNA sequencing of CTC clusters and single CTCs, matched within individual blood samples, identifies the cell junction component plakoglobin as highly differentially expressed. In mouse models, knockdown of plakoglobin abrogates CTC cluster formation and suppresses lung metastases. In breast cancer patients, both abundance of CTC clusters and high tumor plakoglobin levels denote adverse outcomes. Thus, CTC clusters are derived from multicellular groupings of primary tumor cells held together through plakoglobin-dependent intercellular adhesion, and though rare, they greatly contribute to the metastatic spread of cancer.

INTRODUCTION

The metastatic spread of breast cancer, typically to bone, lung, liver, and brain, accounts for the vast majority of cancer-related deaths (Nguyen et al., 2009). Our understanding of epithelial cancer metastasis is derived primarily from mouse models and it is thought to involve a series of sequential steps: epithelial-to-mesenchymal transition (EMT) of individual cells within the primary tumor leading to their intravasation into the bloodstream, survival of such circulating tumor cells (CTCs) within the bloodstream, and finally their extravasation at distant sites, where mesenchymal-to-epithelial transition (MET) culminates in their proliferation as epithelial metastatic deposits (Hanahan and Weinberg, 2011). While EMT has indeed been demonstrated in human breast cancer cells in the circulation (Yu et al., 2013), the requirement for EMT to initiate metastasis has been debated (Ledford, 2011; Tarin et al., 2005). Alternative models proposed include tumor-derived microemboli that may break off from primary tumors, lodging into distal capillaries where they initiate metastatic growth (Fidler, 1973; Liotta et al., 1976; Molnar et al., 2001). Using diverse technological platforms, we and others have indeed detected clusters of CTCs, ranging from 2–50 cancer cells, within the circulation of patients with metastatic epithelial cancers (Cho et al., 2012; Fidler, 1973; Liotta et al., 1976; Molnar et al., 2001; Stott et al., 2010; Yu et al., 2013).

Studies of cancer metastasis have emphasized the concept of “seed versus soil” as a key determinant of metastatic propensity (Fidler, 2003). This model matches the importance of mutated genetic drivers within tumor cells conferring proliferative and invasive properties, with that of the microenvironment of the distant organ or “niche,” which may facilitate metastatic growth. However, the physical characteristics of single CTCs and CTC clusters may also contribute to metastatic propensity, especially as they impact the ability of epithelial tumor cells to survive the loss of cell adherence and shear forces in the bloodstream, i.e., different survival signals among the cancer cell “seeds” may be important. For instance, in a mouse endogenous pancreatic cancer model, noncanonical Wnt signaling is elevated within CTCs, where it appears to suppress anoikis (Yu et al., 2012),...
while in a subcutaneous tumor xenograft model, the admixture of tumor and stromal cells within microemboli may contribute stromal-derived survival signals (Duda et al., 2010). In a recent study of human breast cancer, mesenchymal markers indicative of EMT were expressed within the cancer cells comprising CTC clusters (Yu et al., 2013). Taken together, both human and mouse modeling studies point to the complexity of bloodstream metastasis and the need to capture and characterize CTCs to better understand this process.

CTCs have been detected in the majority of epithelial cancers, where they represent cancer cells captured as they transit through the bloodstream (Alix-Panabières and Pantel, 2013; Yu et al., 2011). As such, they hold the key to understanding critical pathways that mediate the bloodstream dissemination of cancer, which may not be readily evident through analyses of bulk primary or metastatic tumor populations. Factors leading to the generation of CTCs from a primary tumor are unknown, including the fraction derived from cancer cells that have actively invasively into the bloodstream, versus those that are passively shed as a result of compromised tumor vasculature. Although exceedingly rare compared with normal blood cells, the number of CTCs in the bloodstream far exceeds the number of metastatic lesions in patients, indicating that the vast majority CTCs die in the bloodstream, with only a minor fraction representing viable metastatic precursors. Epithelial cells that have lost adhesion-dependent survival signals rapidly undergo anoikis, a fate likely to meet most CTCs in the bloodstream. It is in this context that either mesenchymal transformation, stromal-derived factors, or persistent interepithelial cell junctions may provide survival signals that attenuate this apoptotic outcome (Duda et al., 2010; Mani et al., 2008; Robson et al., 2006; Yu et al., 2012). Dissecting the contributions of these various mechanisms to human cancer requires the ability to isolate individual CTCs from the bloodstream and subject these to detailed molecular analyses.

Multiple technologies have been developed for CTC capture, taking advantage of tumor-specific epitopes absent in normal blood cells, variations in their physical properties such as size, density, and electromechanical characteristics, or by applying high throughput imaging to unpurified blood cell preparations (for review, see Yu et al., 2011). The fact that CTCs are extremely rare, even in patients with advanced metastatic cancers (estimated at one CTC/billion normal blood cells), and that they may be poised on the verge of apoptosis, has made their analysis contingent upon technological constraints. We have introduced a series of microfluidic devices that have the advantage of low-shear, yet high throughput, interrogation of unprocessed whole blood, providing highly enriched and unfixed CTCs that are suitable for detailed molecular analysis (Nagraath et al., 2007; Ozkumur et al., 2013; Stott et al., 2010). Among these, the herringbone (\textsuperscript{16}CTC-Chip) makes use of grooves within the ceiling of the microfluidic chamber to generate turbulent microfluidic flow, directing cells against antibody-coated walls of the device, where CTCs are captured (Stott et al., 2010). This device, whose highly efficient design enabled our initial detection of large CTC clusters, requires on-chip cell lysis for nucleic acid extraction and hence provides an enriched but heterogeneous CTC population for analysis (Yu et al., 2012, 2013). In contrast, our recently described \textsuperscript{16}CTC-iChip achieves highly efficient depletion of erythrocytes and leukocytes from blood specimens, yielding untagged CTCs and small CTC clusters in solution, where they can be micromanipulated for single-cell RNA sequencing (Ozkumur et al., 2013). Here, we use both of these devices, along with in vivo flow cytometry and next generation RNA sequencing, to interrogate CTCs from both patients with metastatic breast cancer and mouse tumor models. We find, using mouse models, that CTC clusters are derived from oligo-clonal clumps of primary tumor cells and constitute a rare but very highly metastasis-competent subset of CTCs, compared with single circulating breast cancer cells. RNA sequencing of human breast CTC clusters identifies plakoglobin as a key mediator of tumor cell clustering, which is expressed in a heterogeneous pattern within the primary tumor. Knockdown of plakoglobin expression in the mouse model suppresses CTC cluster formation and reduces metastatic spread.

RESULTS

Endogenous CTC Clusters Have Increased Metastatic Potential Compared to Single CTCs

To define the origin and functional properties of CTC clusters, compared with single CTCs, we made use of mouse models, where tumor cell composition, transit of CTCs through the bloodstream, and metastatic deposits can be monitored and quantified. We first established a model to test the generation of endogenous CTCs and metastases from a primary orthotopic tumor xenograft. These experiments were designed both to test the metastatic propensity of CTC clusters versus single CTCs, as well as to determine whether CTC clusters originate from an oligoclonal grouping of primary tumor cells or from the clonal progeny of an individual tumor cell. MDA-MB-231-LM2 (LM2) cells, a lung-metastatic variant of MDA-MB-231 human breast cancer cells (Minn et al., 2005), were engineered to express either green fluorescent protein (LM2-GFP) or mCherry (LM2-mCherry), and a 1:1 mixture of these differentially tagged cells was injected into the mammary fat pad of immunodeficient (NSG) mice. As expected, overt primary breast tumors were observed after 5 weeks and these retained an equal distribution of LM2-GFP and LM2-mCherry, as confirmed by IHC staining (Figures S1A and S1B available online). We sampled the blood of tumor-bearing animals for presence of single or clustered CTCs using a terminal bleed and simultaneously harvested the lungs for analysis of metastatic deposits. In addition to enumeration of CTCs, we reasoned that clonally-derived CTC clusters would uniformly express either GFP or mCherry, whereas aggregations of cells from the primary tumor would be heterogeneous for the two markers (Figure 1A). We observed a mean of 2,486 CTC events per mouse (n = 5 mice), of which a mean of 65 (2.6%) were CTC clusters and 2,421 (97.4%) were single CTCs (Figures 1B, 1C, and S2A). Virtually all (91%) CTC clusters were dual positives for GFP and mCherry, and a 1:1 mixture of these differentially tagged cells was injected into the mammary fat pad of immunodeficient (NSG) mice. As expected, overt primary breast tumors were observed after 5 weeks and these retained an equal distribution of LM2-GFP and LM2-mCherry tagged cells, as confirmed by IHC staining (Figures S1A and S1B available online). We sampled the blood of tumor-bearing animals for presence of single or clustered CTCs using a terminal bleed and simultaneously harvested the lungs for analysis of metastatic deposits. In addition to enumeration of CTCs, we reasoned that clonally-derived CTC clusters would uniformly express either GFP or mCherry, whereas aggregations of cells from the primary tumor would be heterogeneous for the two markers (Figure 1A). We observed a mean of 2,486 CTC events per mouse (n = 5 mice), of which a mean of 65 (2.6%) were CTC clusters and 2,421 (97.4%) were single CTCs (Figures 1B, 1C, and S2A). Virtually all (91%) CTC clusters were dual positives for GFP and mCherry. A mean of 5.6 (9%) CTC clusters per mouse (with fewer than three cells per cluster) were comprised of cells expressing only one of the two markers, consistent with expected probabilities given a 1:1 mixture of GFP/mCherry expressing cells in the primary tumor (Figures 1C and S2B). Thus, CTC clusters do not result from the proliferation of a single tumor cell in the vasculature, instead
they appear to represent the aggregation of neighboring cells, most likely within the primary tumor mass (see below).

Metastatic deposits in the lungs were analyzed for both number and composition using anti-GFP and anti-mCherry antibodies, simultaneously with the CTC analyses (Figures 1B, 1C, and S2A). Given the distribution of GFP and mCherry staining in CTC clusters, we reasoned that metastatic tumors derived from a single CTC would be positive for a single marker, while those derived from CTC clusters would stain for both GFP and mCherry (Figures 1A and 1B). A mean of 323 lung foci were identified per mouse (n = 5 mice), of which 171 (53%) were multicolor, and therefore derived from CTC clusters, versus 152 (47%)

See also Figures S1 and S2.
unicolor derivatives of single CTCs (Figures 1C and S2A). Normalizing the number and distribution of lung metastases with that of single CTCs and CTC clusters, we calculate that a CTC cluster is ~50 times more likely to give rise to a metastatic deposit than a single CTC (Figure 1D). Thus, while CTC clusters are much more rare than single CTCs in this orthotopic mouse model of breast cancer, they contribute equally to the metastatic burden in the lung.

To further validate (1) that oligoclonal CTC clusters arise from the fragmenting of primary tumor cell clumps into the vasculature and not from intravascular aggregation of single CTCs, and (2) that oligoclonal lung metastases arise from CTC clusters and not from the reseeding of a metastatic site by multiple single CTCs, we undertook a second series of orthotopic mouse xenograft experiments, injecting LM2-GFP cells into the right mammary fat pad and LM2-mCherry cells in the left fat pad of immunodeficient mice (Figure 1E). Five weeks after injection, mice harbored two independent and differentially tagged tumors, and we again simultaneously harvested the blood for analysis of CTCs and the lungs for enumeration of metastatic deposits. As expected, single CTCs in the circulation demonstrated equal contributions from the GFP and m-Cherry-tagged primary tumors. However, unlike the previous multitagged single tumor model, in mice with two independent individually-tagged tumors, the vast majority of CTC clusters (96%) were of a single color, with equal contributions from GFP- or mCherry-positive primary tumors (Figures 1F, 1G, and S2A). Thus, the vast majority of CTC clusters are derived from individual primary tumors, excluding intravascular aggregation of single CTCs as a significant source of CTC clusters.

A very small fraction of CTC clusters observed in the dual tumor-bearing mice were multicolor (4% of CTC clusters, corresponding to 0.12% of total CTC events) (Figures 1G and S2A). While extraordinarily rare, the presence of such CTC clusters derived from two independent tumors may originate either from the uncommon intravascular aggregation of single CTCs or from a mixing of cancer cells within the two primary tumors, due to the previously reported “tumor reseeding” phenomenon (Kim et al., 2009) (Figure S1B). Consistent with the latter hypothesis, we found that 3%-5% of cells within the GFP-tagged primary tumor were positive for mCherry and 3%-5% of cells within the mCherry-labeled tumor were positive for GFP (Figure S1B). In addition to rare multicolor CTC clusters, we observed a small fraction (8%) of multicolor tumors in the lung (Figures 1G and S2A). These metastatic lesions could result either from the rare multicolor CTC clusters or from the reseeding of metastatic lesions by multiple single CTCs.

We confirmed the findings derived from the two LM2 mouse xenograft experiments with a second, mouse-derived breast cancer cell line, 4T1 (Figures S2C and S2D). Consistent with the LM2 results, a 1:1 mixture of 4T1-GFP and 4T1-mCherry cells within an orthotopic mammary tumor generated CTC clusters that were overwhelmingly multicolored (90%), whereas two separate primary 4T1 tumors labeled either with GFP or mCherry produced CTC clusters that were of a single color (87%). These observations further support that CTC clusters arise as oligoclonal fragments derived from a single tumor (Figure S2C). Normalizing the number and color distribution of 4T1-derived lung metastases relative to the prevalence of single CTCs and CTC clusters, we calculated a 23-fold increase in metastatic competence for CTC clusters versus single CTCs (Figure S2D), an estimate that is comparable to the 50-fold increase derived from LM2 cell experiments. Taken together, these two mouse tumor models indicate that CTC clusters constitute only 2%-5% of all CTC events detected in the circulation, but their dramatically elevated metastatic potential (23–50 times that of single CTCs) contributes to approximately half of all metastatic lesions in orthotopic breast cancer models.

Clustered Cancer Cells Are More Resistant than Single Cells to Apoptosis following Dissemination to the Lung

We generated an in vitro assay that allowed us to obtain a suspension of either single cells or clustered cells (2–30 cells) from cultures of GFP-Luciferase-tagged LM2 cells (see Extended Experimental Procedures). We injected 200,000 LM2 cells prepared either as single cells (LM2-SC) or as clusters (LM2-CL) into the tail vein of immunodeficient mice and subjected them to serial luciferase-based imaging (Figures 2A and 2B). Both LM2-SC and LM2-CL cells reached the lungs with equal efficiency (day 0), as shown by both bioluminescence and GFP immunohistochemical (IHC) staining (Figure 2B). However, over the following days, the LM2-SC lung signal progressively diminished as the cells underwent massive apoptosis, demonstrated by staining for cleaved caspase 3 (Figure 2C). In contrast, the LM2-CL lung signal persisted following intravascular inoculation, with cells showing resistance to apoptosis and tumors expanding more rapidly (Figures 2B–2D). Lung tumors eventually grew in mice subjected to tail vein injection with either of the two LM2 derivatives, but injection of clustered cells resulted in reduced overall survival, with 12.7 weeks for LM2-CL versus 15.7 weeks for LM2-SC (p < 0.016) (Figure 2E). We confirmed the differential rate of apoptosis and metastatic growth in the lung for single versus clustered cancer cells using tail vein injection of two additional breast cancer cell lines, BT474 and 4T1 (Figures S3A–S3D).

Calculation of CTC Clusters and Single CTC Circulatory Clearance Rate Using In Vivo Flow Cytometry

Clusters of tumor cells may exhibit considerable flexibility as they navigate through narrow channels, and capillary beds themselves may have uneven vessel diameters or bypass tracts that allow transit of large multicellular structures. However overall, CTC clusters are more likely than single CTCs to be trapped in small capillaries of the lung and distal organs. Thus, the low steady-state level of CTC clusters in the circulation may reflect a considerably higher generation rate if their clearance rate is very high. To test if CTC clusters indeed have a faster clearance rate from the bloodstream than single CTCs, we used in vivo flow cytometry (IVFC) to monitor LM2-SC and LM2-CL cells labeled with the lipophilic carbocyanine membrane dye DiD, following tail vein injection in immunodeficient mice (Figure 3A). DiD was selected to achieve optimal detection of CTCs with our IVFC settings. Circulating DiD-labeled cells were detected in real time within the ear blood vessels for a total of 55 min in each mouse. Injected LM2-CL cells were cleared at least three times more rapidly than LM2-SC (half-life: 6–10 min for LM2-CL versus 25–30 min for LM2-SC) (Figure 3B). Together, these observations...
define a circulating time for CTCs in the bloodstream: the shorter circulation half-life of CTC clusters is consistent with their more rapid entrapment within capillaries of distal organs, where they may initiate metastatic growth (Liotta et al., 1976).

The Presence of CTC Clusters in Patients with Breast and Prostate Cancer Correlates with Poor Prognosis

Having characterized the origin and metastatic potential of CTC clusters in mouse models, we undertook to study their properties in patients with cancer. To first test the clinical significance of CTC clusters in the blood of patients with progressing metastatic breast cancer, we measured their presence in blood specimens from a total of 79 patients, drawn at multiple time points over a period of 19 months. Patients were recruited to an IRB-approved study at the Massachusetts General Hospital Cancer Center, including women with estrogen receptor-positive (n = 49), HER2-positive (n = 13), triple negative (n = 17) subtypes of breast cancer (total: 265 data points). For these experiments, we made use of the HBCTC-Chip, which is highly efficient in capturing both large and small CTC clusters (Stott et al., 2010). We coated the microfluidic chamber with a combination of antibodies, targeting the epithelial cell adhesion molecule (EpCAM), as well as the lineage markers epithelial growth factor receptor (EGFR) and human epithelial growth factor receptor 2 (HER2/ErbB2), which together efficiently capture both epithelial and mesenchymal breast CTCs (Yu et al., 2013). After processing 3 ml of whole blood from patients with breast cancer, the CTCs captured on the chip were stained with antibodies against wide spectrum cytokeratin (CK) to identify CTCs and against the leukocyte marker CD45 to assess white blood cell (WBC) contamination (Figure 4A). CTCs were identified in 54 out of 79 patients (68%). Among patients with CTCs, 3 (5.6%) had CTC clusters evident across more

Figure 2. CTC Clusters Are More Resistant to Apoptosis at Distal Metastatic Sites

(A) Schematic showing MDA-MB-231-LM2-GFP-Luciferase (LM2) cells prepared as single cells (LM2-SC) or as clusters (LM2-CL) prior to injection into the tail vein of immunodeficient mice. Cells (2 × 10^5) were injected as LM-SC or LM2-CL per mouse. (B) Representative bioluminescence images of mice at 0, 6, and 12 days after tail vein injection with LM2-SC or LM2-CL cells. The bar graph shows the mean percentage of GFP-positive cells in lungs from LM2-SC- or LM2-CL-injected mice. Error bars represent SEM. n = 4; NS, not significant, *p = 0.03 by Student’s t test. (C) Representative images of cleared caspase 3-stained sections of mice lungs 24 hr after injection with LM2-SC or LM2-CL cells. The bar graph shows the mean percentage of cleared caspase 3-positive cells in lungs from LM2-SC- or LM2-CL-injected mice. Error bars represent SEM. n = 4; *p < 0.02 by Student’s t test. (D) Lung metastasis growth curve from mice injected with LM2-SC or LM2-CL. Error bars represent SEM. n = 4; p < 0.03 by Student’s t test. (E) Kaplan-Meier survival plot showing survival rates for mice injected with LM2-SC or LM2-CL. n = 4; p < 0.016 by log rank test. See also Figure S3.
than three time points, while 16 (29.6%) had CTC clusters during one to three time points and 35 (64.8%) had no detectable clusters (Figure 4B). We correlated the presence of CTC clusters with progression-free survival (PFS) for all patients where such data were available (n = 30) (Table S1). Of note, PFS was calculated as time from initiation of therapy to discontinuation by the treating clinician (blinded to the CTC results), and PFS data analysis was performed only when clinical measurements bracketed the CTCs isolation time frame. Patients with CTC clusters across more than three time points had a mean progression-free survival time of 32.6 days, compared with 134.8 days for patients where CTC clusters were found during one to three time points and 160.5 days for patients with single CTCs only (p = 0.0002) (Figure 4C; Table S1). Thus, even among patients with advanced metastatic breast cancer, the continuous presence of CTC clusters is associated with an adverse clinical outcome.

Given the relatively short time to progression in patients with advanced breast cancer, we sought to test the correlation between CTC clusters and adverse prognosis in patients with a longer clinical course. We measured the number of CTCs in a total of 64 patients with prostate cancer using blood specimens drawn at multiple time points over a period of 53 months (total: 202 data points). CTCs in prostate cancer patients were visualized by staining with a cocktail of antibodies against prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA); anti-CD45 staining was used to exclude white blood cells (Miyamoto et al., 2012). CTCs were detected in 48/64 patients (75%). CTC clusters were present in 6/48 samples (12.5%) (Figures 4D and 4E). In this cohort, the presence of CTC clusters during at least one time point strongly correlated with a dramatically shorter overall survival time (mean survival time was 115.8 days for patients with CTC clusters versus 930.1 days for patients with single CTCs; p = 0.00001) (Figure 4F; Table S1). While further studies will be required to ascertain the clinical utility of CTC clusters versus single CTCs as prognostic determinants in either breast or prostate cancer, these initial results point to the potential relevance of CTC clusters in the progression of human cancer.

**Single-Cell Resolution RNA Sequencing of Matched CTC Clusters and Single CTCs Purified from Patients with Breast Cancer**

The ability to capture both single CTCs and CTC clusters from the same blood specimen made it possible to undertake single-cell resolution RNA sequencing, searching for differences in expression profiles matched to individual patients. For these experiments, we applied the nCounter®-chip, which enables isolation and single-cell manipulation of untagged CTCs, together with an optimized protocol for next generation RNA sequencing from minute amounts of template (Ozkumur et al., 2013; Tang et al., 2010). Blood specimens from ten patients with metastatic breast cancer were subjected to microfluidic depletion of RBCs and CD45- and CD66b-positive WBCs, leaving untagged single CTCs and small CTC clusters in the final product (Ozkumur et al., 2013). Unfixed tumor cells were stained for cell surface expression of EpCAM, HER2, and the mesenchymal marker CDH11 (Alexa488-conjugated), and counterstained with antibodies against CD45, CD14, and CD16 to identify contaminating leukocytes (TexasRed-conjugated) (Figure 5A). Individual CTC clusters (median of three cells per cluster) were isolated using a micromanipulator and compared with numerically matched pools of single CTCs from the same specimen, followed by next generation RNA sequencing (SOLiD 5500XL) (Figure 5A).

We derived normalized expression profiles for a total of 29 samples (15 pools of single CTCs and 14 CTC clusters) isolated from ten breast cancer patients.

Unsupervised hierarchical clustering of RNA sequencing data showed no obvious distinctions at the global gene expression level between single CTCs and CTC clusters, with both of these clustering closely by patient of origin (Figure 5B). Consistent with the microscopic appearance of CTC clusters as primarily tumor cell-derived, we did not identify RNA signatures of other cell...
types, including T cells, B cells, dendritic cells, natural killer cells, hematopoietic stem cells, macrophages/microcytes, granulocytes, endothelial cells, or fibroblasts (Figure S4). Markers for platelets were present in both single CTCs and CTC clusters, consistent with their known adherence to cancer cells in the circulation. For each patient, we compared gene expression data of CTC clusters versus single-CTCs, generating a list of 31 CTC-cluster-associated genes shared across different patients (q < 0.01, log2FC > 1, in more than 70% of all intrapatient comparisons) (Figures 5C and 5D; Table S2). To identify potential drivers of metastasis among CTC-cluster-enriched genes, we tested for correlation between their overexpression in primary tumor specimens and clinical outcomes in a cohort of 1,956 patients with ER-positive, HER2-positive, and triple-negative breast tumors, with foci of high expression interspersed with regions without detectable protein (Figure 6B). Thus, while plakoglobin is a key component of intercellular junctions, its variable expression levels within primary tumors raises the possibility that it might demarcate tightly adherent groups of cells that may constitute precursors to CTC clusters.

Plakoglobin (JUP) is a member of the Armadillo family of proteins and an important component of desmosomes and adherence junctions (Aktary and Pasdar, 2012), which has been reported to have both positive and negative roles in diverse malignancies (Hakimelahi et al., 2000; Kolligs et al., 2000; Shiina et al., 2005). Along with upregulation of plakoglobin RNA, multiple components of both desmosomes and adherence junctions were significantly enriched in CTC clusters (Figures S6A–S6E). Consistent with the RNA sequencing results, we confirmed plakoglobin protein expression in multiple CTC clusters, but not in matched single CTCs from a breast cancer patient (Figure 5E).

While CTC clusters express epithelial cell junction components, including plakoglobin and E-cadherin, we have previously shown that some mesenchymal markers may also be upregulated in such clusters, an effect that may be associated with adherence in the bloodstream with TGFβ-rich platelets (Labelle et al., 2011; Yu et al., 2013). Matched primary and metastatic tumors biopsies were available from this patient: plakoglobin expression was remarkably heterogeneous in both the primary and metastatic breast tumors, with foci of high expression interspersed with regions without detectable protein (Figure 6B). Thus, while plakoglobin is a key component of intercellular junctions, its variable expression levels within primary tumors raises the possibility that it might demarcate tightly adherent groups of cells that may constitute precursors to CTC clusters.
Figure 5. RNA Sequencing of CTC Clusters and Single CTCs Reveals a CTC-Clusters-Associated Gene Set

(A) Illustration of the experimental setup (top). Representative images of a labeled white blood cell (WBC, red), a single CTC and a CTC cluster (green) (bottom) are shown.

(B) Heatmap showing unsupervised hierarchical clustering of 15 single CTCs pools and matched 14 CTC clusters isolated from ten breast cancer patients (SC, single CTCs; CL, CTC cluster).

(C) Heatmap showing the top 31 transcripts upregulated in CTC clusters. n = 15 for single CTCs and n = 14 for CTC clusters; q < 0.01, log2 fold change (FC) >1 in more than 70% intrapatient comparisons (SC, single CTCs; CL, CTC cluster).

(D) Graph showing log2 fold increase in plakoglobin ($JUP$) for each comparison between matched CTC clusters versus single CTCs. The threshold line represents a q < 0.01 and log2 fold increase >1.

(E) Representative images of a single CTC and a CTC cluster captured on the HBCTC-Chip from a breast cancer patient and stained with wide-spectrum cytokeratin (CK, red), plakoglobin (green), and DAPI (nuclei, blue).

See also Figure S4 and Table S2.
Plakoglobin Is Required for CTC Cluster Formation and Contributes to Breast Cancer Metastasis

To define the functional consequences of plakoglobin expression in the context of CTC clusters, we first applied an in vitro assay (Vybrant), which utilizes a fluorogenic dye to measure cell-to-cell adhesion under a variety of culture conditions (El Khoury et al., 1996). We compared seven breast cancer cell lines (MDA-MB-231-LM2, BT474, MCF7, T47D, BT549, BT20, and ZR-75-1) with two nontransformed human mammary epithelial cells (HMEC and MCF10A), following stable lentiviral-mediated plakoglobin knockdown. shRNA-mediated plakoglobin suppression triggered disruption of cell-cell contacts in 6/7 breast cancer lines grown as a monolayer, while it had no detectable effect in either of the two nontransformed breast epithelial cells (p < 0.04) (Figures 7A, S7A, and S7B). Thus, breast cancer cells may be more dependent on plakoglobin-mediated cell junctions than normal epithelial cells, which may benefit from additional or alternative pathways in forming intercellular connections (Alford and Taylor-Papadimitriou, 1996; Cavallaro and Christofori, 2004).

To extend these observations in vivo, we introduced either plakoglobin shRNAs or nontarget controls into GFP-Luciferase-tagged LM2 and BT474 cells and prepared these as single cells (SC) or clusters (CL) for tail vein injection into immunosuppressed mice (Figure S7C). Consistent with our previous results, both LM2 and BT474 cells expressing either control or plakoglobin shRNAs into the mammary fat pad of immunodeficient mice and measuring tumor growth as well as tumor-derived CTCs. Plakoglobin knockdown did not alter the primary tumor growth rate, measured for up to 30 days (Figures 7C and S7D), but it did affect the total number of single CTCs derived from the primary tumor (Figure 7D). Remarkably, the number of tumor-derived CTC clusters was significantly reduced in mice bearing LM2 plakoglobin shRNA-expressing tumors compared to control mice (Figure 7D). In parallel, bioluminescence imaging of mouse lungs demonstrated a striking 80% reduction in lung nodules for mice bearing plakoglobin-suppressed primary tumors (Figure 7E).

Together, our data suggest a model whereby plakoglobin-expressing regions within a primary tumor produce aggregated tumor cells, i.e., CTC clusters, that are shed into the bloodstream, where they demonstrate rapid clearing at distant sites and enhanced metastatic potential (Figure 7F). This mechanism of metastatic spread and the possibility that CTC clusters may be targeted therapeutically through disruption of cell-cell junctions provide an opportunity for strategies to reduce the metastatic spread of breast cancer.

DISCUSSION

By applying microfluidic CTC isolation technologies to both patients with breast cancer and mouse models, we have characterized CTC clusters, a striking but poorly understood feature of bloodborne metastasis. CTC clusters have been observed in patients with cancers of different origin and using multiple
technologies (Cho et al., 2012; Fidler, 1973; Liotta et al., 1976; Molnar et al., 2001; Stott et al., 2010; Yu et al., 2013). While most clusters are relatively small, some comprise dozens of tumor cells, raising the question of how they navigate through normal capillaries. Our in vivo flow cytometry studies indicate that clusters are more rapidly cleared from the circulation than single CTCs. Nonetheless, both the structural deformability of the aggregated cells within these clusters and the presence of

Figure 7. Plakoglobin Is Required for CTC Cluster Formation and Lung Metastasis

(A) Bar graph showing the relative cell-to-cell adhesion in a panel of mammary epithelial cells and breast cancer cell lines grown in the presence or absence of plakoglobin. Error bars represent SEM. n = 5; *p < 0.04.

(B) Lung metastasis growth curves from mice injected with LM2-GFP-Luciferase (left) or BT474-GFP-Luciferase (right) cells expressing control or plakoglobin shRNAs and prepared as single cells (SC) or clusters (CL). Error bars represent SEM. n = 4; *p < 0.05, **p < 0.04 by Student’s t test.

(C) LM2-GFP-Luciferase tumor growth curves in the presence or absence of plakoglobin. n = 4; NS, not significant.

(D) Bar graphs showing the normalized number of CTC clusters (left) and single CTCs (right) per ml of blood. Blood samples were isolated 4 weeks after primary tumor development and processed with the HBCTC-Chip. Error bars represent SEM. n = 4; *p < 0.05 by Student’s t test.

(E) Bar graph showing normalized lung photon counts from mice bearing a LM2-GFP-Luciferase control or plakoglobin knockdown primary tumor for 4 weeks. Error bars represent SEM. n = 4; *p < 0.045 by Student’s t test.

(F) Schematic showing that “high plakoglobin” regions in the primary tumor are likely to generate CTC clusters with increased metastatic potential. See also Figure S7.
vascular shunts within the circulation may allow a subset of these to circulate. The rapid clearance of clusters within distal tissues, together with their potentially increased cellular viability may underlie their dramatically enhanced metastatic potential. The increased metastatic propensity of CTC clusters in reconstituted mouse models, together with the adverse prognosis of breast and prostate cancer patients with abundant CTC clusters, support an important role for these cellular aggregates in the bloodborne spread of cancer.

Based on cellular tagging and mixing studies in the mouse, almost all CTC clusters appear to be of oligocolonal origin, rather than being derived from the progeny of a single migratory cell. Our studies exclude intravascular aggregation of CTCs as a significant cause for CTC clusters, demonstrating instead that they originate from a single tumor. We cannot determine whether their entry into the vascular space results from “grouped migration,” an active invasive process that has been described for epithelial cell masses (Friedl and Gilmour, 2009), or passive shedding into compromised tumor vasculature. Interestingly, the high expression of plakoglobin within foci of cells within the primary tumor raises the possibility that these demarcate the origin of clusters that ultimately enter the circulation. In mouse reconstitution models, plakoglobin knockdown in cells that constitute the primary tumor does not suppress tumorigenesis itself, but it abrogates the generation of CTC clusters in the circulation and greatly reduces the number of metastatic deposits in the lung.

The identification of specific transcripts that enhance the metastatic potential of tumor cells may enable therapeutic strategies to suppress the bloodborne spread of cancer, a critical although challenging goal. To date, candidate metastasis genes have been derived primarily from mouse tumor models. Some, like inducers of EMT, alter the migratory properties of breast cancer epithelial cells and confer stem-like properties (Mani et al., 2008). In human breast cancer CTCs, we recently documented enriched expression of genes involved in breast cancer metastases to lung (e.g., Epiregulin, CXCL1, SPARC, and MMP2) (Minn et al., 2005), brain (e.g., COX2, HBEGF, and ST6GALNAC5) (Bos et al., 2009), and bone (mainly driven by Src activation) (Zhang et al., 2009). A recent study interrogating candidate genes in breast CTCs derived from a patient with breast cancer has suggested that coexpression of EpCAM, CD44, CD47, and MET identifies a subset with increased metastatic capacity (Baccelli et al., 2013). While these candidate metastasis genes were not upregulated in CTC clusters compared with single CTCs, our study was not designed to compare CTCs with their matched primary tumors. Finally, we note that our RNA expression studies focused on clusters comprised of tumor cells, because the △CTC-iChip favors isolation of small CTC clusters. We therefore cannot exclude additional contributions from nonmalignant cells within larger microemboli (Duda et al., 2010; Labelle et al., 2011; Stott et al., 2010), including potential stromal-derived tropism signals (Zhang et al., 2013).

Our study identifies mediators of metastasis by comparing two distinct populations of circulating tumor cells, one with very high metastatic potential (CTC clusters) compared with the other (single CTCs). The development of advanced microfluidic CTC isolation technology (Ozkur et al., 2013) enabled us to undertake such a detailed study of human breast cancer cells as they transiently circulate in the bloodstream of patients with metastatic disease. Single-cell resolution RNA sequencing demonstrated a very high level of concordance in expression patterns between matched CTC clusters and single CTCs from individual breast cancer patients. We identified only a small number of candidate genes with significantly divergent expression (Table S2), including transcriptional regulators (XBP1), signaling molecules (AGR2 and HER3), and plakoglobin. While we focused this study on the functional characterization of plakoglobin due to the clinical association between high plakoglobin expression and adverse outcome in patients with breast cancer, additional CTC-cluster-associated genes may be involved in their generation and their metastatic potential. The striking consequences of plakoglobin knockdown, suppressing both CTC cluster generation and metastatic tumor formation in mouse models, point to this gene product being a major determinant of tumor dissemination. Plakoglobin contributes to both adhersions and desmosomes: in adhersions, the C-terminal intracellular domain of E-cadherin interacts in a mutually exclusive manner with either β-catenin or plakoglobin, which in turn associates with the actin-binding protein α-catenin (Harris and Tepass, 2010). At desmosomes, the intracellular domains of desmocollin and desmoglein interact with plakophilin and plakoglobin, which in turn binds the intermediate filament binding protein desmoplakin (Garrod and Chidgey, 2008). Thus, plakoglobin is a critical constituent of both adhersions and desmosomes, a role that may underlie its unique contribution to cell-to-cell adhesion in tumor cells. While plakoglobin has been implicated as both oncogene and tumor suppressor in different contexts (Hakimelahi et al., 2000; Kolligs et al., 2000; Shina et al., 2005), it is neither in the model proposed here, functioning instead as an intercellular tether that confers added metastatic potential to tumor cells as they break off into the circulation. Interestingly, plakoglobin knockdown has far less impact on intercellular connections of nontransformed breast epithelial cells, which may benefit from additional adhesion mechanisms. This differential effect may offer an opportunity for therapeutic intervention.

In summary, our studies of CTCs in both breast and prostate cancer patients and mouse models point to CTC clusters as critical mediators of cancer metastasis. These coexist with single migratory CTCs, making a contribution to the metastatic burden that far exceeds their comparatively small numbers in the circulation. The ability of tumor cell aggregates to detach from a primary tumor and maintain their cohesion as they survive in the bloodstream may identify a novel and potentially targetable step in the bloodborne dissemination of cancer.

**EXPERIMENTAL PROCEDURES**

**CTC Capture and Identification**

Blood specimens for CTC analysis were obtained after informed patient consent, per institutional review board (IRB) protocol (05-300), at the Massachusetts General Hospital. A maximum of 20 ml of blood was drawn in EDTA vacutainers. Within 4 hr from blood draw, ~3 ml of blood was processed through the △CTC-Chip or 6–12 ml of blood was processed through the △CTC-iChip.
For mouse studies, blood was retrieved via cardiac puncture and ~1 ml of blood was processed through the 

\(^{18}\text{F} \)-CTC-Chip.

\(^{18}\text{F} \)-CTC-Chips were manufactured on site at the Massachusetts General Hospital Cancer Center/BioMEMS Resource Facility. For patient samples and mouse xenografts, chips were functionalized as previously described (Yu et al., 2013) with a cocktail of 10 \(\mu\text{g/ml}\) each of biotinylated antibodies against EpCAM (R&D Systems), EGFR (Cetuximab, Lilly), and HER2 (R&D Systems). For 4T1 mouse mammary tumor cells, chips were functionalized with a cocktail of antibodies against EpCAM (BioLegend) and EGFR (Cetuximab, Lilly). Samples from patients with prostate cancer were processed as described (Miyamoto et al., 2012). \(^\text{18}\text{F} \)-CTC-Chips were designed and fabricated as previously described (Ozkurum et al., 2013) (see Extended Experimental Procedures).

**Tumorigenesis Assays**

All mouse experiments were carried out in compliance with institutional guidelines. For tail vein experiments, NOD SCID Gamma (NSG) mice (Jackson Labs) were injected with \(2 \times 10^5\) LM2 cells, \(4 \times 10^5\) BT474 cells, or \(2 \times 10^6\) 4T1 cells and monitored with IVIS Lumina II (Caliper LifeSciences). For CTC clusters metastatic potential assessment, \(2 \times 10^6\) LM2-GFP (or 4T1-GFP) and \(2 \times 10^6\) LM2-mCherry (or 4T1-mCherry) cells were prepared separately or mixed 1:1, suspended in 100 \(\mu\text{l}\) of 50% Basement Membrane Matrix Phenol Red-free (BD Biosciences) in PBS and injected orthotopically in NSG mice. Blood draw for CTCs enumeration was performed 5 weeks after tumor onset. For plakoglobin knockdown experiments, \(1 \times 10^6\) LM2-CTRL or LM2-Plakoglobin shRNA cells were suspended in 100 \(\mu\text{l}\) of 50% Basement Membrane Matrix Phenol Red-free in PBS and injected orthotopically in NSG mice. Blood draw for CTCs enumeration and lung metastasis analysis were performed 4 weeks after tumor onset.

**Analysis of RNA Sequencing**

Determination of reads-per-million (rpm): color space reads were aligned using tophat and bowtie1 with the no-novel-juncs argument set with human genome version hg19 and transcriptome defined by the hg19 knownGene table from http://genome.ucsc.edu. Reads that did not align or aligned to multiple locations in the genome were discarded. The hg19 table knownToLocusLink from http://genome.ucsc.edu was used to map, if possible, each aligned read to the gene whose exons the read had aligned to. The reads count for each gene was the number of reads that were so mapped to that gene. This count was divided by the total number of reads that were mapped to any gene and multiplied by one million to form the reads-per-million (rpm) count. We used rpm rather than rpkm because we noted a 3

\[ \text{reads-per-million (rpm)} = \frac{\text{number of reads mapped to a gene}}{\text{total number of mapped reads}} \times 1,000,000 \]

**REFERENCES**


**SUPPLEMENTAL INFORMATION**

Supplemental Information includes Extended Experimental Procedures, seven figures, and two tables and can be found with this article online at http://dx.doi.org/10.1016/j.cell.2014.07.015.

**AUTHOR CONTRIBUTIONS**

N.A., D.A.H., and S.M. designed and performed the experiments, analyzed the data, and wrote the manuscript. A.B. and D.T.M. provided clinical samples and analyzed clinical data. M.C.D., M.Y., A.E., H.Z., and B.W.B. performed immunofluorescence staining, CTC isolation from patient and mouse blood samples, RNA amplification, and library preparation. B.S.W. and S.R. analyzed the RNA sequencing data. J.A.S., A.P., and C.P.L. performed the in vivo flow cytometry. R.K., S.L.S., T.S., D.T.T., and M.T. provided the CTC isolation technology and the single-cell RNA sequencing platform.

**ACKNOWLEDGMENTS**

We express our gratitude to all the patients who participated in this study. We thank C. Hart, A. McGovern, K. Harrington, L.C. Davis, and the Massachusetts General Hospital (MGH) clinical research coordinators for help with the clinical studies; Drs. P.S. Spuhler and T.A. Barber for support with the CTC-iChip technology; L. Libby and J. Brockmann for excellent technical support. This work was supported by grants from the Breast Cancer Research Foundation (D.A.H.), Stand Up to Cancer (D.A.H., M.T., S.M.), National Foundation for Cancer Research (D.A.H.), Howard Hughes Medical Institute (D.A.H.), NIH CA129933 (D.A.H.), National Institute of Biomedical Imaging and Bioengineering (NIBIB) EB008047 (M.T., D.A.H.), Susan G. Komen for the Cure KG09042 (S.M.), ESSCO Breast Cancer Fund (S.M.), NCI Federal Share Program and Income (S.M.), NIH P41 EB015903-0251 (C.P.L.), NIH P05 CA086355-12 (C.P.L.), and the MGH-Johnson & Johnson Center for Excellence in CTCs (M.T., S.M., M.A. is a fellow of the Human Frontiers Science Program, the Swiss National Science Foundation, and the Swiss Foundation for Grants in Biology and Medicine.

Received: October 21, 2013

Revised: February 14, 2014

Accepted: July 9, 2014

Published: August 28, 2014


